| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CTRV.2008.07.005 |
| P698 | PubMed publication ID | 18922643 |
| P50 | author | Diane C. Bodurka | Q56600503 |
| P2093 | author name string | Judith A Smith | |
| Premal H Thaker | |||
| Judith K Wolf | |||
| Rodney J Hunter | |||
| Marisa A Navo | |||
| P433 | issue | 1 | |
| P921 | main subject | patient | Q181600 |
| obesity | Q12174 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 69-78 | |
| P577 | publication date | 2008-10-14 | |
| P1433 | published in | Cancer Treatment Reviews | Q1955762 |
| P1476 | title | Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). | |
| P478 | volume | 35 |
| Q53592464 | A time to stop, a time to start: high-dose chemotherapy in overweight and obese patients. |
| Q34428550 | Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia |
| Q38225489 | Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter? |
| Q38121735 | Chemotherapy dosing in overweight and obese patients with cancer |
| Q38931979 | Clinical Implications of Sarcopenic Obesity in Cancer. |
| Q39698824 | Comparative outcomes of Thai children with acute lymphoblastic leukemia treated with two consecutive protocols: 11-year experience |
| Q50912268 | Development of a new equation to estimate creatinine clearance in cancer patients. |
| Q33767004 | Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice |
| Q38019839 | Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults |
| Q88963712 | Early breast cancer: why does obesity affect prognosis? |
| Q38037349 | Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review |
| Q42492498 | Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers. |
| Q30404334 | Fiber-optic triggered release of liposome in vivo: implication of personalized chemotherapy |
| Q33432963 | Hematological toxicity of carboplatin for gynecological cancer according to body mass index |
| Q30313786 | Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study |
| Q38697238 | Impact of Body Weight and Body Composition on Ovarian Cancer Prognosis. |
| Q35748477 | Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies |
| Q52897352 | Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking. |
| Q54965039 | Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy. |
| Q35749864 | Is obesity a prognostic factor for acute myeloid leukemia outcome? |
| Q37437967 | Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells |
| Q91000127 | Obesity and cancer treatment efficacy: Existing challenges and opportunities |
| Q57124683 | Obesity and mortality after locoregional breast cancer diagnosis |
| Q37690278 | Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis |
| Q37080304 | Optimal chemotherapy dosing in a bilateral lower extremities amputee with metastatic pancreatic adenocarcinoma |
| Q47406671 | Outcomes after autologous SCT in lymphoma patients grouped by weight |
| Q44927215 | Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight |
| Q34476850 | Pharmacokinetics and drug dosing in obese children |
| Q48085778 | Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine(131)-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma |
| Q44212969 | Relative dose intensity in early stage breast cancer chemotherapy: A retrospective analysis of incidence, risk factors and outcomes at a south-west Sydney cancer clinic |
| Q38469612 | The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients |
| Q36217437 | The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers |
| Q38130610 | Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis |
Search more.